HMNC Brain Health embarks on next phase of growth with new leadership team
|
HMNC Brain Health embarks on next phase of growth with new leadership team
Dr. Franz Humer, longstanding CEO and Chairman of Roche was appointed Chairman of the Board of Directors. In addition, Adalbert Freiherr von Uckermann, Managing Director of the Jahr Group, joined the Board of Directors as a member. Together with Prof. Holsboer and his co-founder, the entrepreneur Carsten Maschmeyer, the Board of Directors is now composed of four top-class executives.
"Our projects are in a promising state of development and now is the right time to entrust the further steps towards market maturity to a new team that is ideally equipped for this task", said Prof. Holsboer. "Our new Chairman of the Board of Directors, Dr. Franz Humer, brings in decades of experience in the pharmaceutical and diagnostics industry as well as plenty of ideas and a unique network to build further partnerships for growth. As Head of the Scientific Board I remain committed to contribute my expertise with the final goal of making it a reality that patients with mental health conditions like depression can be treated with the right medication", Prof. Holsboer added.
- Benedikt von Braunmühl named new CEO
- Dr. Hans Eriksson appointed Chief Clinical Development Officer
- Dr. Franz Humer strengthens Board of Directors as Chairman
- Founder Prof. Dr. Dr. Dr. h.c. mult. Florian Holsboer to lead Scientific Advisory Board
Dr. Franz Humer, longstanding CEO and Chairman of Roche was appointed Chairman of the Board of Directors. In addition, Adalbert Freiherr von Uckermann, Managing Director of the Jahr Group, joined the Board of Directors as a member. Together with Prof. Holsboer and his co-founder, the entrepreneur Carsten Maschmeyer, the Board of Directors is now composed of four top-class executives.
"Our projects are in a promising state of development and now is the right time to entrust the further steps towards market maturity to a new team that is ideally equipped for this task", said Prof. Holsboer. "Our new Chairman of the Board of Directors, Dr. Franz Humer, brings in decades of experience in the pharmaceutical and diagnostics industry as well as plenty of ideas and a unique network to build further partnerships for growth. As Head of the Scientific Board I remain committed to contribute my expertise with the final goal of making it a reality that patients with mental health conditions like depression can be treated with the right medication", Prof. Holsboer added.